Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145379 | 0.79 | MAPT (0.50) | NOTUMMAPTMEN1KMT2AMITF | |
| SCHEMBL1807875 | 0.78 | VCAM1 (0.50) | NOTUMMAPTMEN1KMT2AMITF | |
| SCHEMBL5992360 | 0.78 | VCAM1 (0.60) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1816589 | 0.77 | NOTUM (1.00) | NOTUMMAPTMEN1KMT2AHTT | |
| SCHEMBL1814558 | 0.77 | NOTUM (0.58) | NOTUMMAPTMEN1KMT2AMITF | |
| SCHEMBL2461199 | 0.76 | VCAM1 (0.58) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1813050 | 0.75 | MAPT (0.47) | NOTUMMAPTMEN1KMT2AMITF | |
| SCHEMBL12076512 | 0.75 | NPC1 (0.50) | NOTUMMAPTMEN1KMT2AMITF | |
| SCHEMBL10663504 | 0.74 | MAPT (0.66) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4306926 | 0.74 | POLB (0.53) | NOTUMMAPTMEN1KMT2AMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679266-B | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| CN-101679266-A | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | NOTUM 2607/4885MAPT 4106/4885MEN1 3897/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | NOTUM 2607/4885MAPT 4106/4885MEN1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.